An FDA advisory panel is scheduled to discuss tofersen — Biogen’s investigational drug for amyotrophic lateral sclerosis, which failed to pass its primary endpoint in a late-stage trial — on March 22.
Read the full post on Becker's Hospital Review - Healthcare News
